Evidence map›Paper›PMID 34949698›Full record

ArticleThe European respiratory journal2022

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis.

Jeffrey A Tornheim, Zarir F Udwadia, Prerna R Arora, Ishita Gajjar, Nikhil Gupte, Samridhi Sharma, Megha Karane, Namrata Sawant, Nisha Kharat, Alexander J Blum and 6 more

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Jeffrey A TornheimCenter for Clinical Global Health Education, Division of Infectious Diseases, Dept of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-1566-4622
Zarir F UdwadiaDept of Respiratory Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India zfu@hindujahospital.com.
Prerna R AroraDept of Lab Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Ishita GajjarDept of Lab Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Nikhil GupteCenter for Clinical Global Health Education, Division of Infectious Diseases, Dept of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Samridhi SharmaDept of Lab Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Megha KaraneDept of Lab Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Namrata SawantDept of Lab Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Nisha KharatDept of Lab Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Alexander J BlumJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Shri Vijay Bala Yogendra ShivakumarJohns Hopkins University - India office (CCGHE), Pune, India.
Jai B MullerpattanDept of Respiratory Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Lancelot M PintoDept of Respiratory Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.ORCID 0000-0002-5418-5448
Tester F AshavaidDept of Lab Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, India.
Amita GuptaCenter for Clinical Global Health Education, Division of Infectious Diseases, Dept of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Camilla RodriguesDept of Microbiology, P.D. Hinduja National Hospital and MRC, Mumbai, India.
P. D. Hinduja Hospital and Medical Research Centre · INJohns Hopkins University · US

Funding

The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Fogarty Global Health Fellows Coordinating CenterR25TW009340 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHI, BENJAMIN H. · 2012 to 2016
$6.9M
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)R01AI134430 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HORSBURGH, CHARLES ROBERT, STERLING, TIMOTHY R · 2017 to 2021
$4.6M
A nanopore biosensor for leveling Mtb antigens in bloodR01AI144168 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI Christopher J Lyon · 2022 to 2026
$3.0M
Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in bloodR01AI175618 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI Zhen Huang, Jeffrey Tornheim · 2023 to 2026
$2.9M
Whole Genome Sequencing of Drug Resistant Tuberculosis in India: Genotype-Phenotype Correlation, Clinical Impact of Resistance, and Sequencing Directly from SputumK23AI135102 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TORNHEIM, JEFFREY · 2018 to 2021
$776k
A novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient hostR21AI122922 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2016 to 2017
$446k
FIC NIH HHS R25 TW009340NIAID NIH HHS K23 AI135102NIAID NIH HHS R01 AI134430NIAID NIH HHS R01 AI144168NIAID NIH HHS R01 AI175618NIAID NIH HHS R21 AI122922NIAID NIH HHS UM1 AI069465
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CycloserineTuberculosis, Multidrug-ResistantAntitubercular AgentsDepressionHumansIncidenceAntitubercular AgentsCycloserine

Identifiers

PMID34949698
PMCPMC8943271
OpenAlexW4200039313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.